Governor Moore Welcomes Syngene International Pharmaceutical Manufacturing Facility to Baltimore City
BALTIMORE, MD (August 12, 2025) — Governor Wes Moore is pleased to welcome Syngene International, a global research, development, and biotech pharmaceutical manufacturing company, to Baltimore City—its first facility in the United States. The company is expected to create 300 jobs and be fully operational by the end of the year, with additional growth anticipated as the company further integrates into the U.S. market, at its 100,000 square-foot biologics manufacturing site at 5901 E. Lombard Street.
“We are excited to welcome Syngene International to Maryland as they expand their presence in the U.S. market,” said Gov. Moore. “As one of the nation’s leading states in biopharma, Maryland offers the ideal location for Syngene to build its footprint while creating jobs, driving innovation, and growing Baltimore’s economy.”
Headquartered in Bengaluru, India, Syngene International provides research, development, and manufacturing services to pharmaceutical, biotech, nutrition, and other specialty industries worldwide. The company recently acquired the state-of-the-art Baltimore biologics manufacturing facility for $36.5 million and plans to invest another $13.5 million in renovations.
The project site will be adapted for monoclonal antibody (mAb) production, advancing Syngene’s global biologics strategy and addressing growing demand from domestic and international mAb developers seeking a manufacturing presence.
The project marks the establishment of Syngene International’s first facility in the United States (Syngene USA Inc.). The new site will expand Syngene’s total bioreactor capacity, further supporting mAb production, discovery, and manufacturing. It will also enhance customer supply chain continuity by integrating with Syngene’s existing development and manufacturing sites across India and North America.
“We are very pleased to start our U.S. manufacturing operations in Maryland, with the facility in Bayview, Baltimore,” said Syngene International Managing Director and Chief Executive Officer Peter Bains. “The state-of-the-art biologics facility will complement our India based operations and increase Syngene’s total single-use bioreactor capacity to 50,000L for large molecule discovery, development, and manufacturing services. Maryland is one of the leading biopharma clusters in the U.S. and we are excited to contribute to this vibrant ecosystem and the region’s economy.”
Lt. Governor Aruna Miller met with Syngene’s leadership at the BIO International Convention earlier this summer, where the company exhibited its entrance into Maryland.
“I am thrilled that Syngene International will soon call Maryland home,” said Lt. Governor Aruna K. Miller. “Their investment here represents more than jobs—it’s a partnership. One that strengthens our economy, supports cutting-edge research, and drives progress in health and medicine not only for Marylanders, but for people across the globe. We are thrilled to stand with Syngene at the forefront of biotech innovation and we look forward to growing and building the future—together.”
With Genetic Engineering & Biotechnology News again naming the Capital Region as the #3 biopharma cluster in the country, this announcement builds on Maryland’s leadership in the life sciences. The Maryland Department of Commerce and the Baltimore Development Corporation continue to assist Syngene with the ongoing planning and development surrounding its new manufacturing facility.
“We are proud to see a global leader like Syngene choose Baltimore City for this significant investment,” said Maryland Department of Commerce Secretary Harry Coker, Jr. “The facility will not only bring hundreds of quality jobs and economic growth to our state, but it also reinforces Maryland’s leadership in the life sciences sector. We look forward to supporting Syngene as they expand their U.S. operations.”
“Reactivating this large facility in East Baltimore is a major step forward for our city,” said Baltimore Development Corporation President and Chief Executive Officer Otis Rolley. “Syngene’s decision to launch its first U.S. venture here in Baltimore reflects the global confidence in our talent, our infrastructure, and our future. This international investment brings hundreds of jobs, new partnerships, and real momentum to Baltimore’s life sciences ecosystem. BDC is proud to partner with Syngene to help make this a long-term success for the company and for our city.”
For Syngene media inquiries, please contact:
Pramuch Goel, Head of Corporate Affairs
Syngene International Limited
E: pramuch.goel@syngeneintl.com
M: +91-9818887234
About Maryland Commerce
The Maryland Department of Commerce stimulates private investment and creates jobs by attracting new businesses, encouraging the expansion and retention of existing companies, and providing financial assistance to Maryland companies. The Department promotes the State’s many economic advantages and markets local products and services at home and abroad to spur economic development and international investment, trade and tourism. Because they are major economic generators, the Department also supports the Arts, film production, sports and other special events. For more information, visit commerce.maryland.gov.
